TJ396B - A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia. - Google Patents

A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia.

Info

Publication number
TJ396B
TJ396B TJ96000330A TJ96000330A TJ396B TJ 396 B TJ396 B TJ 396B TJ 96000330 A TJ96000330 A TJ 96000330A TJ 96000330 A TJ96000330 A TJ 96000330A TJ 396 B TJ396 B TJ 396B
Authority
TJ
Tajikistan
Prior art keywords
variants
human dnase
treatment
patient suffering
purified
Prior art date
Application number
TJ96000330A
Other languages
English (en)
Inventor
John Frenz
Steven J Shire
Mary B Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of TJ396B publication Critical patent/TJ396B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TJ96000330A 1992-06-08 1993-05-28 A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia. TJ396B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/895,300 US5279823A (en) 1992-06-08 1992-06-08 Purified forms of DNASE
PCT/US1993/005136 WO1993025670A1 (en) 1992-06-08 1993-05-28 Purified forms of dnase

Publications (1)

Publication Number Publication Date
TJ396B true TJ396B (en) 2004-12-29

Family

ID=25404292

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000330A TJ396B (en) 1992-06-08 1993-05-28 A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia.

Country Status (30)

Country Link
US (4) US5279823A (ro)
EP (2) EP1013284B1 (ro)
JP (1) JP3383307B2 (ro)
KR (2) KR100302092B1 (ro)
AT (2) ATE455557T1 (ro)
AU (1) AU682822B2 (ro)
BG (1) BG62335B1 (ro)
BR (1) BR9306670A (ro)
CA (1) CA2137237C (ro)
CZ (1) CZ293105B6 (ro)
DE (3) DE69334317D1 (ro)
DK (1) DK0644932T3 (ro)
ES (1) ES2150447T3 (ro)
FI (1) FI945549A7 (ro)
GB (1) GB2282140B (ro)
GE (1) GEP20002300B (ro)
GR (1) GR3034718T3 (ro)
HU (1) HU219549B (ro)
IL (1) IL105724A (ro)
MD (1) MD960288A (ro)
NO (1) NO318644B1 (ro)
NZ (1) NZ253559A (ro)
PL (1) PL175873B1 (ro)
PT (1) PT644932E (ro)
RO (1) RO117188B1 (ro)
RU (1) RU2238320C2 (ro)
SK (1) SK282957B6 (ro)
TJ (1) TJ396B (ro)
UA (1) UA46693C2 (ro)
WO (1) WO1993025670A1 (ro)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
JP2986215B2 (ja) 1994-03-04 1999-12-06 ジェネンテック インコーポレイテッド Ｄｎアーゼ含有医薬製剤
CA2184581C (en) * 1994-03-04 2005-02-22 Hak-Kim Chan Improved dnase liquid solutions
US6251648B1 (en) 1998-04-03 2001-06-26 Human Genome Sciences, Inc. Gene encoding human Dnase
US5830744A (en) * 1995-06-06 1998-11-03 Human Genome Sciences, Inc. Gene encoding human Dnase
EP0817839A1 (en) * 1994-05-05 1998-01-14 Human Genome Sciences, Inc. Human dnase
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis
WO1996007735A1 (en) * 1994-09-06 1996-03-14 Seiichi Tanuma Novel deoxyribonuclease
US5863563A (en) * 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
SK284191B6 (sk) 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
NZ331063A (en) * 1996-02-05 2000-03-27 Inc Genentech Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition
US6482626B2 (en) * 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
KR101036414B1 (ko) * 1998-05-06 2011-05-23 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
AU2001235009B2 (en) * 2000-02-11 2004-10-07 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
DK1285080T3 (da) 2000-05-31 2008-12-01 Novartis Vaccines & Diagnostic Fremgangsmåde til oprensning af alphavirusreplikonpartikler
MD20010375A (ro) * 2001-11-19 2003-06-30 АНДРИЕВСКИ Сергей Malaxor
MD2260C2 (ro) * 2001-11-22 2004-03-31 АНДРИЕВСКИ Сергей Malaxor
WO2004024866A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Protein purification
US7067298B2 (en) * 2003-03-31 2006-06-27 Ambion, Inc. Compositions and methods of using a synthetic Dnase I
US7595179B2 (en) * 2004-04-19 2009-09-29 Applied Biosystems, Llc Recombinant reverse transcriptases
EP1861507A4 (en) * 2005-02-04 2008-06-25 Glaxo Group Ltd OPTIMIZATION OF THE EXPRESSION OF HETEROLOGOUS POLYPEPTIDES
KR100655438B1 (ko) * 2005-08-25 2006-12-08 삼성전자주식회사 자기 기억 소자 및 그 형성 방법
US20080044851A1 (en) * 2006-06-02 2008-02-21 Epicentre Technologies Compositions and methods for removal of DNA from a sample
BRPI0717439A2 (pt) * 2006-10-18 2013-11-19 Periness Ltd Composição farmacêutica, e, métodos para tratar subfertilidade masculina, para determinar um estado de fertlidade em um indivíduo do sexo masculino, para a reprodução assistida, para selecionar uma técnica de reprodução assistida e para selecionar células de esperma em uma população de células de esperma para uso em uma técnica de reprodução auxiliada.
PL2840090T3 (pl) 2007-10-30 2018-07-31 Genentech, Inc. Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
WO2009123950A2 (en) * 2008-03-31 2009-10-08 The Trustees Of The University Of Pennsylvania Chimera comprising bacterial cytotoxin and methods of using the same
US9226976B2 (en) 2011-04-21 2016-01-05 University Of Massachusetts RAAV-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
WO2013114374A1 (en) * 2012-02-01 2013-08-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
CN103920144B (zh) * 2013-01-15 2016-09-14 吴庄民 重组人的脱氧核糖核酸酶i的新应用
AU2015279831A1 (en) * 2014-06-25 2017-01-12 Jhl Biotech, Inc. Methods and reagents for purification of proteins
EP3214172B1 (en) 2014-10-31 2019-02-13 JCR Pharmaceuticals CO., LTD. Method for producing remcombinant human dnasei
CA2988471A1 (en) * 2015-07-28 2017-02-02 University Of Massachusetts Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector
CA3012344A1 (en) 2016-02-12 2017-08-17 University Of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
WO2018094167A1 (en) 2016-11-17 2018-05-24 Iovance Biotherapeutics, Inc. Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
WO2021244964A1 (en) 2020-06-01 2021-12-09 Black Cat Bio Limited Compositions and methods for treating infections and netopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2801956A (en) * 1954-08-24 1957-08-06 Merck & Co Inc Process for preparing pancreatic desoxyribonuclease
US2834710A (en) * 1955-06-29 1958-05-13 Merck & Co Inc Pancreatic desoxyribonuclease penicillin composition and process of preparation
US3208908A (en) * 1961-11-16 1965-09-28 Parke Davis & Co Fibrinolysin-desoxyribonuclease for enzymatic debridement
US3663690A (en) * 1969-08-12 1972-05-16 Hoechst Co American Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith
CA1059937A (en) * 1975-03-25 1979-08-07 Boen T. Khouw Isolation and purification of deoxyribonuclease
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE

Also Published As

Publication number Publication date
BG99234A (bg) 1995-07-28
BR9306670A (pt) 1998-12-08
AU682822B2 (en) 1997-10-23
UA46693C2 (uk) 2002-06-17
US5279823A (en) 1994-01-18
NZ253559A (en) 1996-11-26
KR100302092B1 (ko) 2001-10-22
FI945549A0 (fi) 1994-11-25
MD960288A (ro) 1998-01-31
CA2137237A1 (en) 1993-12-23
NO944752D0 (no) 1994-12-08
ES2150447T3 (es) 2000-12-01
WO1993025670A1 (en) 1993-12-23
GB2282140B (en) 1996-04-17
DE4392749T1 (de) 1995-07-20
BG62335B1 (bg) 1999-08-31
GEP20002300B (en) 2000-11-25
EP1013284A3 (en) 2000-08-30
RU2238320C2 (ru) 2004-10-20
KR100323357B1 (ko) 2002-02-19
RO117188B1 (ro) 2001-11-30
JP3383307B2 (ja) 2003-03-04
FI945549L (fi) 1994-11-25
CA2137237C (en) 2004-10-26
FI945549A7 (fi) 1994-11-25
HUT70468A (en) 1995-10-30
EP1013284B1 (en) 2010-01-20
US20030077267A1 (en) 2003-04-24
NO318644B1 (no) 2005-04-25
HU9403512D0 (en) 1995-02-28
HU219549B (hu) 2001-05-28
GR3034718T3 (en) 2001-01-31
NO944752L (no) 1994-12-08
EP1013284A2 (en) 2000-06-28
ATE455557T1 (de) 2010-02-15
US6932965B2 (en) 2005-08-23
EP0644932A1 (en) 1995-03-29
PT644932E (pt) 2001-02-28
US5783433A (en) 1998-07-21
JPH07507455A (ja) 1995-08-24
IL105724A (en) 1997-06-10
PL175873B1 (pl) 1999-02-26
CZ293105B6 (cs) 2004-02-18
SK282957B6 (sk) 2003-01-09
US6440412B1 (en) 2002-08-27
DK0644932T3 (da) 2001-01-02
EP0644932B1 (en) 2000-08-09
ATE195340T1 (de) 2000-08-15
GB9423695D0 (en) 1995-01-11
RU94046424A (ru) 1997-03-10
DE69329200T2 (de) 2001-04-26
DE69329200D1 (de) 2000-09-14
CZ303294A3 (en) 1995-06-14
GB2282140A (en) 1995-03-29
IL105724A0 (en) 1993-09-22
SK149594A3 (en) 1996-01-10
DE69334317D1 (de) 2010-03-11
AU4398193A (en) 1994-01-04

Similar Documents

Publication Publication Date Title
TJ396B (en) A process for resolving a mixture of human dnase (variants), purified deamidated human dnase, purified non-deamidated human dnase, a pharmaceutical composition for reducing viscoelasticity of purulentmaterial (variants), a method for the treatment o f a patient suffering from accumulation of purulent material (variants), a method for the treatment of a patient suffering from cystic fibrosis, bronchitis, pneumonia.
HUT41809A (en) Process for preparing dideoxy-nucleosides and pharmaceutical compositions containing such compounds
CA2163112A1 (en) A coagulation factor viii formulation
ATE223230T1 (de) Pulmonäre verabreichung des löslichen komplement- receptors typ 1 scr1
DE69327582D1 (de) Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
IL79379A0 (en) Carboxylic acid derivatives,process for the preparation thereof and pharmaceutical compositions containing them
AU1412088A (en) Therapeutic nucleosides
IL83775A (en) Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
MY104124A (en) Therapeutic compounds.
ZA894945B (en) Strontium salt,process for the preparation thereof and pharmaceutical compositions containing it
KR100288019B1 (ko) 뮤신분비 억제제
FR2592793A1 (fr) Association de sulpiride et de diazepam a titre de composition pharmaceutique, notamment utile dans le traitement des manifestations fonctionnelles digestives liees au stress, et son utilisation pour la preparation de ladite composition.